Valneva’s Chikungunya Vaccine Gains EU Approval for Adolescents

Valneva ( (VALN) ) has shared an announcement.

Valneva SE announced that the European Commission has granted marketing authorization for its chikungunya vaccine, IXCHIQ®, for adolescents aged 12 and above in the EU, Norway, Liechtenstein, and Iceland. This approval, dated April 1, 2025, marks a significant milestone in expanding access to the vaccine, which is already approved for adults in the EU, U.S., Canada, and the U.K. The vaccine addresses a significant unmet medical need as chikungunya continues to spread globally, with outbreaks in regions such as India, Brazil, and La Réunion. The EC’s approval is supported by positive Phase 3 data showing a strong immune response in adolescents, and Valneva is focused on further expanding the vaccine’s access, including efforts to provide it at an affordable price in low- and middle-income countries.

More about Valneva

Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. The company has a strong track record in advancing vaccines from early R&D to approvals and currently markets three proprietary travel vaccines, including the world’s first chikungunya vaccine.

YTD Price Performance: 42.16%

Average Trading Volume: 48,278

Technical Sentiment Signal: Hold

Current Market Cap: $542.6M

See more data about VALN stock on TipRanks’ Stock Analysis page.